Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.34 |
| ▸ | NQO2 | P16083 | 3/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22434774 | 0.89 | ACLY (0.34) | CYP19A1NQO2HSD11B1ACLY | |
| SCHEMBL22434780 | 0.86 | CYP19A1 (0.36) | CYP19A1NQO2 | |
| SCHEMBL20505201 | 0.82 | HASPIN (0.33) | CYP19A1NQO2PTGS2 | |
| SCHEMBL15704627 | 0.76 | CYP19A1 (0.36) | CYP19A1NQO2 | |
| SCHEMBL24136151 | 0.75 | ACLY (0.34) | ACLY | |
| SCHEMBL22434877 | 0.75 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL22434885 | 0.74 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL22434867 | 0.74 | — | — | |
| SCHEMBL22434866 | 0.74 | HSD11B1 (0.36) | HSD11B1 | |
| SCHEMBL22434670 | 0.72 | PKM (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-02-08 | — | — | US | disclosed |
| EP-3928836-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2021-12-29 | — | — | EP | disclosed |
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | CYP19A1 255/4885NQO2 693/4885HSD11B1 305/4885 |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | CYP19A1 255/4885NQO2 693/4885HSD11B1 305/4885 |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | CYP19A1 255/4885NQO2 693/4885HSD11B1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.